目的：探讨阿魏酸哌嗪联合厄贝沙坦治疗早期糖尿病肾病（ diabetic kidney disease ，DKD）患者的临床效果。方法将126例早期DKD患者随机分为两组，各63例。两组均给予常规治疗，观察组在常规治疗的基础上加用阿魏酸哌嗪和厄贝沙坦，而对照组只加用厄贝沙坦，观察比较两组治疗效果及治疗前后尿微量白蛋白（ UAER）、尿β2微球蛋白（β2-MG）及血肌酐（Scr）的变化情况。结果治疗后，观察组总有效率为92．1％，高于对照组的76．2％（ P ＜0．05）。治疗前，两组患者UAER、β2-MG及Scr水平差异均无统计学意义（ P ＞0．05）；治疗后，两组UAER、β2-MG及Scr 水平均有明显下降（ P ＜0．01）；观察组UAER和β2-MG下降幅度大于对照组（ P ＜0．01）。结论阿魏酸哌嗪联合厄贝沙坦治疗早期糖尿病肾病可明显改善患者症状，提高肾脏功能，临床治疗效果显著，并可改善预后。%Objective To explore the effect of irbesartan and ferulic acid piperazine combined treatment of diabetic nephropa -thy.Methods One hundred and twenty-six patients with diabetic nephropathy were randomly divided into study group and the control group(n=63,each),and all the patients received conventional treatment and the study group was given additional drugs of Eritrea irbe -sartan and ferulic acid piperazine ,while patients in the control group was given irbesartan .The treatment effect,UAER,Scr,SBP,andβ2-MG of the two groups before and after treatment were observed and compared .Results After treatment the total efficacy rate of ob-servation group was 92.1%,higher than 76.2%of control group( P <0.05).Before treatment, levels of UAER, Scr and β2-MG of the two groups showed no significant difference ( P >0.05).After treatment,levels of UAER, Scr andβ2-MG of the two groups showed a significant decrease ( P <0.01).Levels of UAER and β2-MG of the observation group decreased more obviously than that of control group ( P <0.01).Conclusion The two drugs used in combination can significantly improve the patient 's symptoms,renal function and prognosis .
展开▼
